Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01537887 · ClinicalTrials.gov registry record · Phase 1

A Study of LY2484595 on the Electrical Activity of the Heart

A Phase 1 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target

NCT01537887 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01537887, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the effect on the electrical activity of the heart as measured by an electrocardiogram (ECG) after dosing with 10 days of LY2484595 compared to 10 days of placebo in relation to a single dose of moxifloxacin. Information about any side effects that occur will also be collected.

Interventions

  • DRUG Placebo
  • DRUG Moxifloxacin
  • DRUG LY2484595

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2012-02
Est. Completion 2012-06
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT01537887

The ClinicalTrials.gov registry entry for NCT01537887 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01537887 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01537887 about?

NCT01537887 is a clinical study titled "A Study of LY2484595 on the Electrical Activity of the Heart". The purpose of this study is to evaluate the effect on the electrical activity of the heart as measured by an electrocardiogram (ECG) after dosing with 10 days of LY2484595 compared to 10 days of placebo in relation to a single dose of moxifloxacin. Information about any side effects that occur will...

What is the current status of trial NCT01537887?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2012-02. Estimated completion is 2012-06.

What interventions are being tested in trial NCT01537887?

The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), LY2484595 (DRUG).

Who is sponsoring clinical trial NCT01537887?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.